Columbus Venture Partners

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.

Integra Therapeutics is focused on advancing gene editing technologies to address various diseases. The company is developing innovative gene writing tools that aim to enhance the effectiveness of gene therapy. By combining the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in the field of gene editing. This approach allows scientists to introduce DNA into a genome using sequence-specific DNA binding proteins, thereby facilitating the development of targeted gene therapies that meet the specific needs of patients.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Bioncotech is a development stage bio-pharma company focused on the development of a new concept of anticancer therapy for the treatment of tumors such as metastatic melanoma, glioblastoma, bladder, or pancreatic cancer. The company is a spin-off of the Spanish National Cancer Research Centre, one of the leading international centers in cancer research. It Therapeutics is a biopharmaceutical company dedicated to the development of new oncologic treatments. The company develops and manages projects throughout the value-creation chain: from formulation, manufacturing, and preclinical development to clinical trials with the support of other institutions and pharmaceutical companies. Founded in 2012 by [Maria Gonzalez](https://www.crunchbase.com/person/maria-gonzalez-2), Bioncotech is headquartered in Paterna with other designations in Madrid, Spain and Cambridge, Massachusetts.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.